Download PDF
Dialyse aktuell 2010; 14: S24-s27
DOI: 10.1055/s-0031-1272890
Biosimilars

© Georg Thieme Verlag Stuttgart · New York

EPO-Hyporesponse – Strategien für eine effektive Therapie

EPO hyporesponse – Strategies for an effective therapyMark Dominik Alscher1
  • 1Abteilung für Allgemeine Innere Medizin und Nephrologie, Zentrum für Innere Medizin, Robert-Bosch-Krankenhaus, Stuttgart (Chefarzt: Prof. Dr. Mark Dominik Alscher)
Further Information

Publication History

Publication Date:
26 January 2011 (online)

Also available at
    Permissions and Reprints

Die Anämie bei einer chronischen Funktionseinschränkung der Niere ist multifaktoriell bedingt. Der Erythropoetinmangel ist im Zentrum der Aufmerksamkeit und der Therapie. Man muss aber die begleitenden Faktoren berücksichtigen. Ansonsten ist die EPO-Therapie unwirksam. Häufig wird die renale Anämie von Eisenmangel, Eisenverwertungsstörungen bei akuten oder chronischen Entzündungszuständen, sekundärem Hyperparathyreoidismus und weiteren, seltenen Faktoren begleitet. Diese Komponenten muss man bei einem fehlenden Ansprechen der renalen Anämie auf EPO-Gaben analysieren. Eine EPO-Hyporesponse ist definiert als ein fehlendes Ansprechen über 4–6 Monate nach der Substitution von mehr als 300 IE EPO pro kg Körpergewicht pro Woche. Die Differenzialdiagnose der EPO-Hyporesponse und die Abklärung können schematisiert erfolgen. Unter einer danach erfolgenden gezielten Behandlung ist die Substitution im Regelfall effektiv.

The causes of anemia in chronic renal failure are multiple. The deficiency of erthyropoetine is in the centre of the awareness of the caregivers. However, the accompanying factors also have to be put into account. Otherwise, failure of EPO therapy is the result. Renal anemia often is combined with iron deficiencies, iron achrestic pictures seen with acute or chronic inflammations, secondary hyperparathyreoidism and more, rare factors. These components have to be analyzed if failure of EPO therapy is diagnosed. The definition of EPO hyporesponse is as following: not reaching target hemoglobin levels after the use of more than 300 IU EPO per kg bodyweight per week for 4–6 months. The work-up of the differential diagnosis can be following a flow-sheet. With target-aimed therapy, EPO becomes effective again.

Key words

erythropoetin - kidney - anemia - dialysis - iron deficiency - hyperparathyreoidism - infection - inflammation

Literatur

  • 1 Bradbury BD, Danese MD, Gleeson M, Critchlow CW.. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.  Clin J Am Soc Nephrol. 2009;  4 630-637
    CrossrefGoogle Scholar
  • 2 Zhang Y, Thamer M, Stefanik K et al.. Epoetin requirements predict mortality in hemodialysis patients.  Am J Kidney Dis. 2004;  44 866-876
    Google Scholar
  • 3 Kausz AT, Solid C, Pereira BJ et al.. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?.  Am J Kidney Dis. 2005;  45 136-147
    CrossrefGoogle Scholar
  • 4 IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.  Am J Kidney Dis. 2001;  37 182-238
    CrossrefGoogle Scholar
  • 5 Drueke TB, Locatelli F, Clyne N et al.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 2071-2084
    CrossrefGoogle Scholar
  • 6 Locatelli F, Aljama P, Barany P et al.. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.  Nephrol Dial Transplant. 2004;  19 (S 02) 1-47
    CrossrefGoogle Scholar
  • 7 Hutchinson FN, Jones WJ.. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.  Am J Kidney Dis. 1997;  29 651-657
    CrossrefGoogle Scholar
  • 8 Loge JP, Lange RD, Moore CV.. Characterization of the anemia associated with chronic renal insufficiency.  Am J Med. 1958;  24 4-18
    CrossrefGoogle Scholar
  • 9 Silverberg DS, Iaina A, Peer G et al.. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.  Am J Kidney Dis. 1996;  27 234-238
    CrossrefGoogle Scholar
  • 10 Erslev AJ, Besarab A.. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure.  Kidney Int. 1997;  51 622-630
    CrossrefGoogle Scholar
  • 11 Eschbach JW.. Iron requirements in erythropoietin therapy.  Best Pract Res Clin Haematol. 2005;  18 347-361
    CrossrefGoogle Scholar
  • 12 Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Casc L n, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L.. Diagnosis of iron deficiency in chronic renal failure.  Am J Kidney Dis. 1999;  34 508-513
    CrossrefGoogle Scholar
  • 13 Kaufman JS, Reda DJ, Fye CL et al.. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.  Kidney Int. 2001;  60 300-308
    CrossrefGoogle Scholar
  • 14 Danielson B.. R-HuEPO hyporesponsiveness -- who and why?.  Nephrol Dial Transplant. 1995;  10 (S 02) 69-73
    Google Scholar
  • 15 Drueke TB.. R-HuEPO hyporesponsiveness -- who and why?.  Nephrol Dial Transplant. 1995;  10 (S 02) 62-68
    Google Scholar
  • 16 Goicoechea M, Martin J, de Sequera P et al.. Role of cytokines in the response to erythropoietin in hemodialysis patients.  Kidney Int. 1998;  54 1337-1343
    CrossrefGoogle Scholar
  • 17 Gunnell J, Yeun JY, Depner TA, Kaysen GA.. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.  Am J Kidney Dis. 1999;  33 63-72
    CrossrefGoogle Scholar
  • 18 Lopez-Gomez JM, Perez-Flores I, Jofre R et al.. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.  J Am Soc Nephrol. 2004;  15 2494-2501
    CrossrefGoogle Scholar
  • 19 Alscher DM, Mettang T.. Procalcitonin in peritoneal dialysis--a useful marker of inflammation?.  Perit Dial Int. 2005;  25 441-444
    Google Scholar
  • 20 Roberts TL, Obrador GT, St WL Peter et al.. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.  Kidney Int. 2004;  66 2429-2436
    CrossrefGoogle Scholar
  • 21 Rao DS, Shih MS, Mohini R.. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.  N Engl J Med. 1993;  328 171-175
    CrossrefGoogle Scholar
  • 22 Klemm A, Sperschneider H, Lauterbach H, Stein G.. Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment?.  Clin Nephrol. 1994;  42 343-345
    Google Scholar
  • 23 Zachee P, Chew SL, Daelemans R, Lins RL.. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment.  Am J Nephrol. 1992;  12 188-191
    CrossrefGoogle Scholar
  • 24 Casadevall N, Dupuy E, Molho-Sabatier P et al.. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.  N Engl J Med. 1996;  334 630-633
    CrossrefGoogle Scholar
  • 25 Casadevall N, Nataf J, Viron B et al.. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.  N Engl J Med. 2002;  346 469-475
    CrossrefGoogle Scholar
  • 26 McKoy JM, Stonecash RE, Cournoyer D et al.. Epoetin-associated pure red cell aplasia: past, present, and future considerations.  Transfusion. 2008;  48 1754-1762
    CrossrefGoogle Scholar
  • 27 Macdougall IC, Rossert J, Casadevall N et al.. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.  N Engl J Med. 2009;  361 1848-1855
    CrossrefGoogle Scholar
  • 28 Tomson CR, Edmunds ME, Chambers K et al.. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.  Nephrol Dial Transplant. 1992;  7 817-821
    Google Scholar
  • 29 Griffing GT, Melby JC.. Enalapril (MK-421) and the white cell count and haematocrit.  Lancet. 1982;  1 1361
    Google Scholar
  • 30 Fyhrquist F, Karppinen K, Honkanen T et al.. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril.  J Intern Med. 1989;  226 257-260
    CrossrefGoogle Scholar
  • 31 Kamper AL, Nielsen OJ.. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy.  Scand J Clin Lab Invest. 1990;  50 611-618
    CrossrefGoogle Scholar
  • 32 Kaiser L, Schwartz KA.. Aluminum-induced anemia.  Am J Kidney Dis. 1985;  6 348-352
    Google Scholar
  • 33 Ifudu O, Feldman J, Friedman EA.. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.  N Engl J Med. 1996;  334 420-425
    CrossrefGoogle Scholar
  • 34 Movilli E, Cancarini GC, Zani R et al.. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.  Nephrol Dial Transplant. 2001;  16 111-114
    CrossrefGoogle Scholar
  • 35 Locatelli F, Andrulli S, Pecchini F et al.. Effect of high-flux dialysis on the anaemia of haemodialysis patients.  Nephrol Dial Transplant. 2000;  15 1399-1409
    CrossrefGoogle Scholar
  • 36 Richardson D, Lindley EJ, Bartlett C, Will EJ.. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.  Am J Kidney Dis. 2003;  42 551-560
    CrossrefGoogle Scholar
  • 37 Opatrny Jr. K, Reischig T, Vienken J et al.. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis.  Artif Organs. 2002;  26 181-188
    CrossrefGoogle Scholar
  • 38 Locatelli F, Andrulli S, Memoli B et al.. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.  Nephrol Dial Transplant. 2006;  21 991-998
    CrossrefGoogle Scholar
  • 39 Hurot JM, Cucherat M, Haugh M, Fouque D.. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review.  J Am Soc Nephrol. 2002;  13 708-714
    Google Scholar
  • 40 Priyadarshi A, Shapiro JI.. Erythropoietin resistance in the treatment of the anemia of chronic renal failure.  Semin Dial. 2006;  19 273-278
    CrossrefGoogle Scholar

Korrespondenz

Prof. Dr. Mark Dominik Alscher

Abteilung für Allgemeine Innere Medizin und Nephrologie Zentrum für Innere Medizin Robert-Bosch-Krankenhaus

Auerbachstraße 110

70376 Stuttgart

Email: dominik.alscher@rbk.de

      >